<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
<journal-id journal-id-type="hwp">jbc</journal-id>
<journal-id journal-id-type="pmc">jbc</journal-id>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-title-group>
<journal-title>The Journal of Biological Chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9258</issn>
<issn pub-type="epub">1083-351X</issn>
<publisher>
<publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
<publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27555326</article-id>
<article-id pub-id-type="pmc">5063988</article-id>
<article-id pub-id-type="publisher-id">M116.749119</article-id>
<article-id pub-id-type="doi">10.1074/jbc.M116.749119</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurobiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells<xref ref-type="fn" rid="FN1">*</xref></article-title>
<alt-title alt-title-type="short">Pharmacological Chaperones of the Dopamine Transporter</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3721-3213</contrib-id>
<name>
<surname>Beerepoot</surname>
<given-names>Pieter</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="author-notes" rid="FN2">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lam</surname>
<given-names>Vincent M.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="author-notes" rid="FN3">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salahpour</surname>
<given-names>Ali</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor1">
<sup>3</sup>
</xref>
</contrib>
<aff id="aff1">From the Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>3</label> To whom correspondence should be addressed: <addr-line>Dept. of Pharmacology and Toxicology, Rm. 4302, Medical Sciences Bldg., 1 King's College Circle, Toronto, Ontario M5S 1A8.</addr-line> Tel.: <phone>416-978-2046</phone>; Fax: <fax>416-978-6395</fax>; E-mail: <email>ali.salahpour@utoronto.ca</email>.</corresp>
<fn fn-type="supported-by" id="FN2">
<label>1</label>
<p>Supported by OGS (Ontario Graduate Scholarship) and CIHR (Canadian Institutes of Health Research) awards.</p>
</fn>
<fn fn-type="supported-by" id="FN3">
<label>2</label>
<p>Supported by OGS and NSERC (Natural Science and Engineering Research Council) awards.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>14</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>8</month>
<year>2016</year>
</pub-date>
<volume>291</volume>
<issue>42</issue>
<fpage>22053</fpage>
<lpage>22062</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>8</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Â© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>The American Society for Biochemistry and Molecular Biology, Inc.</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="zbc04216022053.pdf"></self-uri>
<abstract>
<p>A number of pathological conditions have been linked to mutations in the dopamine transporter gene, including hereditary dopamine transporter deficiency syndrome (DTDS). DTDS is a rare condition that is caused by autosomal recessive loss-of-function mutations in the dopamine transporter (DAT), which often affects transporter trafficking and folding. We examined the possibility of using pharmacological chaperones of DAT to rescue DTDS mutations. After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect. Bupropion and ibogaine increased wild type DAT protein levels and also promoted maturation of the endoplasmic reticulum (ER)-retained DAT mutant K590A. Rescue of K590A could be blocked by inhibiting ER to Golgi transport using brefeldin A. Furthermore, knockdown of coat protein complex II (COPII) component SEC24D, which is important in the ER export of wild type DAT, also blocked the rescue effects of bupropion and ibogaine. These data suggest that bupropion and ibogaine promote maturation of DAT by acting as pharmacological chaperones in the ER. Importantly, both drugs rescue DAT maturation and functional activity of the DTDS-associated mutations A314V and R445C. Together, these results are the first demonstration of pharmacological chaperoning of DAT and suggest this may be a viable approach to increase DAT levels in DTDS and other conditions associated with reduced DAT function.</p>
</abstract>
<kwd-group>
<kwd>chaperone</kwd>
<kwd>COPII</kwd>
<kwd>dopamine transporter</kwd>
<kwd>membrane protein</kwd>
<kwd>protein folding</kwd>
<kwd>DTDS</kwd>
<kwd>SEC24D</kwd>
<kwd>bupropion</kwd>
<kwd>ibogaine</kwd>
<kwd>pharmacological chaperone</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>Ministry of Research and Innovation
<named-content content-type="funder-id">http://dx.doi.org/10.13039/501100003400</named-content></funding-source>
<award-id>Early Research Award</award-id>
</award-group>
<award-group id="award2">
<funding-source>Canadian Institutes of Health Research
<named-content content-type="funder-id">http://dx.doi.org/10.13039/501100000024</named-content></funding-source>
<award-id>Doctoral Research Award</award-id>
</award-group>
<award-group id="award3">
<funding-source>Natural Sciences and Engineering Research Council of Canada
<named-content content-type="funder-id">http://dx.doi.org/10.13039/501100000038</named-content></funding-source>
<award-id>Doctoral Award</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>